Tiing Leong Ang

Tiing Leong Ang

Auto-generated profile, based on publicly available information

Tiing Leong Ang

Department of Gastroenterology and Hepatology Changi General Hospital Singapore

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2009 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
KFK Ming Fock
K Ming Fock
PKPeter Katelaris
Peter Katelaris
KSKentaro Sugano
Kentaro Sugano
TATiing Leong Ang
Tiing Leong Ang
RHRichard Hunt
Richard Hunt
ARAbdul Aziz Rani
Abdul Aziz Rani
The Asia–Pacific Consensus Conference was convened to review and synthesize the most current information on Helicobacter pylori management so as to update the previously published regional guidelines. The group recognized that in addition to long‐established indications, such as peptic ulcer disease, early mucosa‐associated lymphoid tissue (MALT) type lymphoma and family history of gastric cancer, H. pylori eradication was also indicated for H. pylori infected patients with functional dyspepsia, in those receiving long‐term maintenance proton pump inhibitor (PPI) for gastroesophageal reflux disease, and in cases of unexplained iron deficiency anemia or idiopathic thrombocytopenic purpura. In addition, a population ‘test and treat’ strategy for H. pylori infection in communities with high incidence of gastric cancer was considered to be an effective strategy for gastric cancer prevention. It was recommended that H. pylori infection should be tested for and eradicated prior to long‐term aspirin or non‐steroidal anti‐inflammatory drug therapy in patients at high risk for ulcers and ulcer‐related complications. In Asia, the currently recommended first‐line therapy for H. pylori infection is PPI‐based triple therapy with amoxicillin/metronidazole and clarithromycin for 7 days, while bismuth‐based quadruple therapy is an effective alternative. There appears to be an increasing rate of resistance to clarithromycin and metronidazole in parts of Asia, leading to reduced efficacy of PPI‐based triple therapy. There are insufficient data to recommend sequential therapy as an alternative first‐line therapy in Asia. Salvage therapies that can be used include: (i) standard triple therapy that has not been previously used; (ii) bismuth‐based quadruple therapy; (iii) levofloxacin‐based triple therapy; and (iv) rifabutin‐based triple therapy. Both CYP2C19 genetic polymorphisms and cigarette smoking can influence future H. pylori eradication rates.

4 March 2008 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
KFKwong Ming Fock
Kwong Ming Fock
NTNick Talley
Nick Talley
PMPaul Moayyedi
Paul Moayyedi
RHRichard Hunt
Richard Hunt
TATakeshi Azuma
Takeshi Azuma
JSJose Sollano
Jose Sollano
Background and Aim:  Gastric cancer is a major health burden in the Asia–Pacific region but consensus on prevention strategies has been lacking. We aimed to critically evaluate strategies for preventing gastric cancer.Methods:  A multidisciplinary group developed consensus statements using a Delphi approach. Relevant data were presented, and the quality of evidence, strength of recommendation, and level of consensus were graded.Results:  Helicobacter pylori infection is a necessary but not sufficient causal factor for non‐cardia gastric adenocarcinoma. A high intake of salt is strongly associated with gastric cancer. Fresh fruits and vegetables are protective but the use of vitamins and other dietary supplements does not prevent gastric cancer. Host–bacterial interaction in H. pylori infection results in different patterns of gastritis and differences in gastric acid secretion which determine disease outcome. A positive family history of gastric cancer is an important risk factor. Low serum pepsinogens reflect gastric atrophy and may be useful as a marker to identify populations at high risk for gastric cancer. H. pylori screening and treatment is a recommended gastric cancer risk reduction strategy in high‐risk populations. H. pylori screening and treatment is most effective before atrophic gastritis has developed. It does not exclude the existing practice of gastric cancer surveillance in high‐risk populations. In populations at low risk for gastric cancer, H. pylori screening is not recommended. First‐line treatment of H. pylori infection should be in accordance with national treatment guidelines.Conclusion:  A strategy of H. pylori screening and eradication in high‐risk populations will probably reduce gastric cancer incidence, and based on current evidence is recommended by consensus.

25 February 2010 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
KFKwong Ming Fock
Kwong Ming Fock
TATiing Leong Ang
Tiing Leong Ang

3 June 2016 in Gut
Verified
Journal Article
Closed access
PDF file
KFKwong Ming Fock
Kwong Ming Fock
NTNicholas Talley
Nicholas Talley
KGKhean Lee Goh
Khean Lee Goh
KSKentaro Sugano
Kentaro Sugano
PKPeter Katelaris
Peter Katelaris
SBShobna Bhatia
Shobna Bhatia
Objective Since the publication of the Asia-Pacific consensus on gastro-oesophageal reflux disease in 2008, there has been further scientific advancement in this field. This updated consensus focuses on proton pump inhibitor-refractory reflux disease and Barrett's oesophagus. Methods A steering committee identified three areas to address: (1) burden of disease and diagnosis of reflux disease; (2) proton pump inhibitor-refractory reflux disease; (3) Barrett's oesophagus. Three working groups formulated draft statements with supporting evidence. Discussions were done via email before a final face-to-face discussion. We used a Delphi consensus process, with a 70% agreement threshold, using Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria to categorise the quality of evidence and strength of recommendations. Results A total of 32 statements were proposed and 31 were accepted by consensus. A rise in the prevalence rates of gastro-oesophageal reflux disease in Asia was noted, with the majority being non-erosive reflux disease. Overweight and obesity contributed to the rise. Proton pump inhibitor-refractory reflux disease was recognised to be common. A distinction was made between refractory symptoms and refractory reflux disease, with clarification of the roles of endoscopy and functional testing summarised in two algorithms. The definition of Barrett's oesophagus was revised such that a minimum length of 1 cm was required and the presence of intestinal metaplasia no longer necessary. We recommended the use of standardised endoscopic reporting and advocated endoscopic therapy for confirmed dysplasia and early cancer. Conclusions These guidelines standardise the management of patients with refractory gastro-oesophageal reflux disease and Barrett's oesophagus in the Asia-Pacific region.

13 December 2007 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
KFKwong Ming Fock
Kwong Ming Fock
NTNicholas J Talley
Nicholas J Talley
RFRonnie Fass
Ronnie Fass
KGKhean Lee Goh
Khean Lee Goh
PKPeter Katelaris
Peter Katelaris
SMSathoporn Manatsathit
Sathoporn Manatsathit

1 September 2008 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
SSStefan Seewald
Stefan Seewald
TATiing Leong Ang
Tiing Leong Ang
HIHiroo Imazu
Hiroo Imazu
MNMazen Naga
Mazen Naga
SOSalem Omar
Salem Omar
NSNib Soehendra
Nib Soehendra